Kyowa Hakko Kirin Co., Limited

Kyowa Kirin Co., Ltd.

Takeyoshi Yamashita

Takashi Shimada

Yuji Yamazaki

Hitoshi Yoshida

Itaru Urakawa

Yukiko Aono

Hisashi Hasegawa

Seiji Fukumoto

Satoru Mizutani

To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).

Anti FGF23 antibody and a pharmaceutical composition comprising the same

A method for treating a hypophosphatemic bone disease, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition, which contains an antibody that binds to an FGF-23 polypeptide and a pharmaceutically acceptable carrier.

Method for treating hypophosphatemic bone diseases using FGF-23 antibody

The purpose of the present invention is to provide an antibody against fibroblast growth factor 23. The antibody is obtained by immunizing an animal with a polypeptide which comprises an amino acid sequence represented by SEQ ID NO: 1, or an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 1 by deletion, substitution, or addition of 1 or several amino acids, and has fibroblast growth factor-23 activity and activity to control phosphate metabolism or vitamin D metabolism, and is shown by the following (a), (b), or (c):

Antibody against fibroblast growth factor-23

Growing community of inventors

Tokyo, Japan

Takeyoshi Yamashita